Clinical Trials

Find trials by condition, location & phase

Drug Monographs

Browse drug monographs and information

Explore organizations and their profiles

Latest updates on trials and healthcare

Approved products by global authorities

AI-Powered Research

Discover powerful insights with advanced AI analysis tools for clinical trials.

Premium Access

Get unlimited access to our comprehensive pharmaceutical database and analytics.

Memorial Sloan Kettering Cancer Center

🇺🇸United States

Country: 🇺🇸United States

Ownership: Private

Established: 1884-01-01

Employees: 10K

Market Cap: -

Website: http://www.mskcc.org

Clinical Trials

MRI Parenchymal Enhancement: A New Marker of Breast Cancer Risk

Completed

Conditions: Cancer Free Women

Interventions: Behavioral: questionnaire

First Posted Date: 2012-07-25

Last Posted Date: 2023-01-26

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Target Recruit Count: 437

Registration Number: NCT01649661

Locations: 🇺🇸
Memorial Sloan Kettering Cancer Center, New York, New York, United States

Primary Transplant Donor Derived CMVpp65 Specific T-cells for The Treatment of CMV Infection or Persistent CMV Viremia After Allogeneic Hematopoietic Stem Cell Transplantation

Phase 2

Completed

Conditions: Cytomegalovirus

Interventions: Biological: CMV-pp65 CTLs

First Posted Date: 2012-07-20

Last Posted Date: 2020-12-16

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Target Recruit Count: 58

Registration Number: NCT01646645

Locations: 🇺🇸
Memorial Sloan Kettering Cancer Center, New York, New York, United States

Study of (1) Everolimus, (2) Estrogen Deprivation Therapy (EDT) With Leuprolide + Letrozole and (3) Everolimus + EDT in Patients With Unresectable Fibrolamellar Hepatocellular Carcinoma (FLL-HCC)

Phase 2

Completed

Conditions: Fibrolamellar Carcinoma
Fibrolamellar Liver Cancer

Interventions: Drug: letrozole plus leuprolide
Drug: combination of everolimus, letrozole and leuprolide
Drug: everolimus

First Posted Date: 2012-07-17

Last Posted Date: 2022-12-29

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Target Recruit Count: 28

Registration Number: NCT01642186

Locations: 🇺🇸
University of California San Francisco, San Francisco, California, United States
🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸
John Hopkins Medical Center, Baltimore, Maryland, United States

and more 3 locations

Cabozantinib in Patients With RET Fusion-Positive Advanced Non-Small Cell Lung Cancer and Those With Other Genotypes: ROS1 or NTRK Fusions or Increased MET or AXL Activity

Phase 2

Recruiting

Conditions: Non-Small Cell Lung Cancer

Interventions: Drug: Cabozantinib

First Posted Date: 2012-07-12

Last Posted Date: 2024-06-25

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Target Recruit Count: 86

Registration Number: NCT01639508

Locations: 🇺🇸
Memorial Sloan Kettering Basking Ridge, Basking Ridge, New Jersey, United States
🇺🇸
Memorial Sloan Kettering Monmouth, Middletown, New Jersey, United States
🇺🇸
Memorial Sloan Kettering Bergen, Montvale, New Jersey, United States

and more 4 locations

Developing Culturally-Tailored Information-Based Support Groups for Chinese Immigrants With Breast Cancer

Withdrawn

Conditions: Chinese Immigrants With Breast Cancer

Interventions: Behavioral: in-person support group
Behavioral: virtual support group

First Posted Date: 2012-07-04

Last Posted Date: 2014-02-06

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Registration Number: NCT01632956

Locations: 🇺🇸
Queens Cancer Center of Queens Hospital, Jamaica, New York, United States

Improving End of Life Care in Head and Neck Cancer

Terminated

Conditions: Upper Aerodigestive Tract
The Families or Next of Kin of Patients Treated at MSKCC for Non-cutaneous Squamous Cell Carcinomas of the

Interventions: Behavioral: The The Family Assessment of Treatment at the End of life (FATE ) survey

First Posted Date: 2012-07-04

Last Posted Date: 2015-03-06

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Target Recruit Count: 2

Registration Number: NCT01632969

Locations: 🇺🇸
Memorial Sloan Kettering Cancer Center, New York, New York, United States

Gemcitabine and Pazopanib in Chemotherapy Naïve Patients With Advanced/Metastatic Urothelial Carcinoma Ineligible for Cisplatin-based Chemotherapy

Phase 2

Terminated

Conditions: Bladder Cancer

Interventions: Drug: Gemcitabine
Drug: Pazopanib

First Posted Date: 2012-06-19

Last Posted Date: 2017-08-22

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Target Recruit Count: 2

Registration Number: NCT01622660

Locations: 🇺🇸
Memorial Sloan Kettering Cancer Center @ Suffolk, Commack, New York, United States
🇺🇸
Memoral Sloan Kettering Cancer Center, Basking Ridge, New Jersey, United States
🇺🇸
Memorial Sloan Kettering Cancer Center, New York, New York, United States

and more 2 locations

18F-FLT-PET Imaging of the Brain in Patients With Metastatic Breast Cancer to the Brain Treated With Whole Brain Radiation Therapy With or Without Sorafenib: Comparison With MR Imaging of the Brain

Not Applicable

Completed

Conditions: Metastatic Breast Cancer to the Brain

Interventions: Device: 18F-FLT-PET Imaging

First Posted Date: 2012-06-18

Last Posted Date: 2022-09-09

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Target Recruit Count: 17

Registration Number: NCT01621906

Locations: 🇺🇸
Memoral Sloan Kettering Cancer Center, Basking Ridge, New Jersey, United States
🇺🇸
Memorial Sloan Kettering Monmouth, Middletown, New Jersey, United States
🇺🇸
Memorial Sloan Kettering Cancer Center @ Suffolk, Commack, New York, United States

and more 3 locations

Observational Longitudinal Study of Pain in Men With Metastatic Castrate-Resistant Prostate Cancer

Withdrawn

Conditions: Prostate Cancer

Interventions: Behavioral: Webcore telephone survey system

First Posted Date: 2012-06-12

Last Posted Date: 2013-11-08

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Registration Number: NCT01617174

Tumor Perfusion and Hypoxia Assessed by DCE-MRI and 18F-FMISO PET as Biomarkers of Treatment Response in Cervical Cancer

Not Applicable

Terminated

Conditions: Cervical Cancer

Interventions: Other: DCE-MRI and 18F-FMISO PET

First Posted Date: 2012-06-07

Last Posted Date: 2014-03-13

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Target Recruit Count: 3

Registration Number: NCT01613521

Locations: 🇺🇸
Memorial Sloan Kettering Cancer Center, New York, New York, United States

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy